Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Nair, A.
Right arrow Articles by Fuster, V.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Nair, A.
Right arrow Articles by Fuster, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Anticoagulation in patients with heart failure: who, when, and why?

Ajith Nair1,{dagger}, Brett Sealove1,{dagger}, Jonathan L. Halperin2, Geoffrey Webber1 and Valentin Fuster2,*

1 Mount Sinai Medical Center, New York, NY, USA
2 Zena and Michael A. Wiener Cardiovascular Institute, Marie-Josée and Henry R. Kravis Center for Cardiovascular Health, Mount Sinai Medical Center, New York, NY, USA

* Corresponding author. Tel: +1 212 241 7911; fax: +1 212 423 9488. E-mail address: valentin.fuster{at}mssm.edu

The mortality rate associated with advanced heart failure (HF) remains high. Although pharmacological and device therapy have improved survival in patients with HF or depressed systolic function, antithrombotic therapy is controversial. Autopsy studies demonstrated a high incidence of arterial and venous thrombo-embolism in patients with HF, but secondary analyses of clinical trials have suggested lower rates of stroke and clinical thrombo-embolic events, perhaps because a relatively high percentage of patients had atrial fibrillation (AF) and were treated with anticoagulants. Although anticoagulation is recommended for patients with AF who have HF or reduced left ventricular ejection fraction (EF), guidelines vary regarding antithrombotic therapy for patients without AF. Those with ischaemic heart disease are typically treated with a platelet inhibitor such as aspirin. Further studies are needed to define the incidence of venous or right-sided intracardiac source of thrombo-embolism in patients with HF or reduced EF, as this may be an under-recognized cause of morbidity and mortality. Ongoing studies will provide more insight into the selection of optimum antithrombotic therapy and better assess the net impact of such therapy on event-free survival in patients with advanced HF.

Key Words: Heart failure • Anticoagulation • Aspirin • Thrombo-embolism • Atrial fibrillation


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 StrokeHome page
N. S. Rost, S. M. Greenberg, and J. Rosand
The Genetic Architecture of Intracerebral Hemorrhage
Stroke, July 1, 2008; 39(7): 2166 - 2173.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.